This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.70% and 2.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.
GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View
by Zacks Equity Research
Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.
Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) aims at product innovation through R&D.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.
Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand
by Zacks Equity Research
It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.
ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) Beats on Q2 Earnings, Margins Fall
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies.
Integra Lifesciences' (IART) Earnings Top Estimates in Q2
by Zacks Equity Research
We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.
Baxter (BAX) Beats on Q2 Earnings & Revenues, Ups EPS View
by Zacks Equity Research
Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.
NextGen (NXGN) Q1 Earnings Lag Estimates, Revenues Down Y/Y
by Zacks Equity Research
NextGen (NXGN) slashes guidance for fiscal 2020 owing to a dismal Q1.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Varian (VAR) expects revenue growth in the range of 9-10% for fiscal 2019.
Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.
Thermo Fisher (TMO) Beats on Q2 Earnings, Lifts Guidance
by Zacks Equity Research
Banking on a strong operational performance, Thermo Fisher (TMO) raises its 2019 revenue and earnings guidance.
Neogen's (NEOG) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Neogen's (NEOG) strong international business and solid performance by core Food Safety segment resulted in year-over-year revenue growth.
Boston Scientific (BSX) Q2 Earnings Top on Growth in All Lines
by Zacks Equity Research
Boston Scientific's (BSX) revenue strength across all business lines and geographies raises investors' optimism on the stock.
Medidata (MDSO) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental contributions in Q2.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.
Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.
Abbott (ABT) Tops Q2 Earnings Estimates, Lifts EPS Guidance
by Zacks Equity Research
Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.
Henry Schein Closes Acquisition of Elite Computer Italia
by Zacks Equity Research
The Elite Computer acquisition marks Henry Schein's (HSIC) foray into the Italian dental practice management software market.